% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

  • b_zerkley b_zerkley Mar 2, 2001 9:00 AM Flag

    The smart move here...

    would be for NYMX to go to J&J and offer to screen 10,000 high risk patients for $99.00 (or less if possible) per patient as part of the Reminyl launch. J&J would probably kick in part of the price to help Dr.'s identify patients at risk. Tying the diagnostic to a therapy, especially one in launch mode, could significantly raise the visability of the test to physicians. To accelerate the usage and acceptance of this test, you need major pharma sponsor support.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.5164-0.2136(-5.73%)11:58 AMEDT